Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer.


Journal

Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310

Informations de publication

Date de publication:
10 2019
Historique:
received: 02 03 2019
accepted: 20 06 2019
revised: 15 05 2019
pubmed: 28 6 2019
medline: 13 2 2020
entrez: 28 6 2019
Statut: ppublish

Résumé

Stage-specific embryonic antigen-4 (SSEA-4), a specific marker for pluripotent stem cells, plays an important role in the malignant behavior of several cancers. Here, SSEA-4 expression was evaluated by immunohistochemistry using monoclonal antibody RM1 specific to SSEA-4 in 181 and 117 prostate cancer (PC) specimens obtained by biopsy and radical prostatectomy (RP), respectively. The relationships between SSEA-4 expression in cancer cells or the presence of SSEA-4-positive tumor-infiltrating immune cells (TICs) and clinicopathological parameters were analyzed. SSEA-4 expression in cancer cells was significantly associated with Gleason score, local progression, and lymph node and distant metastasis. In RP specimens, high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs were significant predictors of pT3, i.e., invasion and worse biochemical recurrence (BCR) after RP, respectively, in univariate analysis. In contrast, combination of high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs was an independent predictor for pT3 and BCR in multivariate analysis. Biologically this combination was also independently associated with suppression of apoptosis. Thus, the co-expression of SSEA-4 in cancer cells and TICs may have crucial roles in the malignant aggressiveness and prognosis of PC. Invasive potential and suppression of apoptosis may be linked to SSEA-4 expression.

Identifiants

pubmed: 31243630
doi: 10.1007/s10719-019-09882-2
pii: 10.1007/s10719-019-09882-2
pmc: PMC6744380
doi:

Substances chimiques

Biomarkers, Tumor 0
Glycosphingolipids 0
Stage-Specific Embryonic Antigens 0
stage-specific embryonic antigen-4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-418

Références

J Cell Mol Med. 2016 Apr;20(4):721-30
pubmed: 26849468
Oncol Lett. 2010 May;1(3):417-421
pubmed: 22966318
Glycobiology. 2015 Aug;25(8):902-17
pubmed: 25978997
Transl Res. 2016 Sep;175:116-28
pubmed: 27140699
J Biol Chem. 2015 Jun 26;290(26):16043-58
pubmed: 25940087
Oral Oncol. 2013 Aug;49(8):787-95
pubmed: 23768762
J Cancer Res Clin Oncol. 2010 May;136(5):787-93
pubmed: 19946707
Sci Rep. 2016 Jan 20;6:16993
pubmed: 26787499
FEBS Lett. 2002 Oct 30;531(1):93-8
pubmed: 12401210
J Cancer Res Clin Oncol. 2017 Nov;143(11):2393-2400
pubmed: 28823006
J Immunol. 2009 Oct 15;183(8):5050-8
pubmed: 19801523
Clin Genitourin Cancer. 2019 Feb;17(1):e221-e226
pubmed: 30472041
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2482-7
pubmed: 24550271
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2517-22
pubmed: 23355685
Int J Cancer. 2009 Nov 15;125(10):2323-31
pubmed: 19598259
Sci Rep. 2015 Apr 08;5:9604
pubmed: 25853231
J Biol Chem. 1994 Feb 25;269(8):5644-52
pubmed: 7509790
Urology. 2005 Jun;65(6):1238-43
pubmed: 15922418
Breast Cancer Res. 2015 Nov 25;17(1):146
pubmed: 26607327
Nat Commun. 2011 Jan 18;2:162
pubmed: 21245843
Prostate. 2019 Feb;79(3):320-330
pubmed: 30488530
J Biol Chem. 2003 Jul 18;278(29):26474-9
pubmed: 12716912
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Eur Respir J. 2013 Mar;41(3):656-63
pubmed: 22743677
EMBO J. 1983;2(12):2355-61
pubmed: 6141938
Oncotarget. 2017 Nov 6;9(63):32238-32249
pubmed: 30181813
Anticancer Res. 2007 Nov-Dec;27(6C):4345-50
pubmed: 18214042
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):40-5
pubmed: 20018687

Auteurs

Yuichiro Nakamura (Y)

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Yasuyoshi Miyata (Y)

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. yasu-myt@nagasaki-u.ac.jp.

Tomohiro Matsuo (T)

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Yohei Shida (Y)

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Tomoaki Hakariya (T)

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Kojiro Ohba (K)

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Takenobu Taima (T)

Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, 980-8574, Japan.

Akihiro Ito (A)

Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, 980-8574, Japan.

Tetsuji Suda (T)

Department of Urology, University of the Ryukyus, Okinawa, 903-0215, Japan.

Sen-Itiroh Hakomori (SI)

Departments of Pathobiology and Global Health, University of Washington, Seattle, WA, 98112, USA.

Seiichi Saito (S)

Department of Urology, University of the Ryukyus, Okinawa, 903-0215, Japan.

Hideki Sakai (H)

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH